



Q Search drug, target, indication, organization...

⚡ Sign Up for Free

Login



🔄 Last update 25 May 2025

Ga68-ITM-74D

- Overview
- R&D Status
- Clinical Result
- Translational Medicine
- Deal
- Core Patent
- Clinical Trial
- Approval
- Regulation

Overview

Basic Info

Drug Type:	Diagnostic radiopharmaceuticals
Synonyms:	Ga-68-ITM-74D, Ga68-ITM-74D, ITM 74D ⚡ + [1]
Target:	FAP
Action:	antagonists
Mechanism:	FAP antagonists(Fibroblast activation protein alpha antagonists)
Therapeutic Areas:	Neoplasms Other Diseases
Active Indication:	Fibrosis Inflammation Neoplasms
Inactive Indication:	-
Originator Organization:	🏢 Itm Isotope Technologies Munich SE
Active Organization:	🏢 Itm Isotope Technologies Munich SE
Inactive Organization:	-
License Organization:	-
Drug Highest Phase:	Phase 1
First Approval Date:	-
Regulation:	-

⚡ Login to view timeline

Related

Clinical Results associated with Ga68-ITM-74D

⚡ Login to view more data

Translational Medicine associated with Ga68-ITM-74D

⚡ Login to view more data

Patents (Medical) associated with Ga68-ITM-74D

⚡ Login to view more data

Deals associated with Ga68-ITM-74D

⚡ Login to view more data

R&D Status

top R&D records. [Login](#) to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Fibrosis	Phase 1	Germany	 Itm Isotope Technologies Munich SE	01 Mar 2025
Inflammation	Phase 1	Germany	 Itm Isotope Technologies Munich SE	01 Mar 2025
Neoplasms	Phase 1	Germany	 Itm Isotope Technologies Munich SE	01 Mar 2025

⚡ Login to view more data

Clinical Result ⓘ


 Indication ▼  Phase ▼  Evaluation ▼  View All Results

Study	Phase ⓘ	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date
 No Data							

⚡ Login to view more data

Translational Medicine


Boost your research with our translational medicine data.
[login](#) or [view full example data](#)



Deal

Boost your decision using our deal data.


[login](#) or [view full example data](#)



Core Patent

Boost your research with our Core Patent data.

[login](#) or [view full example data](#)



Clinical Trial

Identify the latest clinical trials across global registries.

[login](#) or [view full example data](#)



Approval

Accelerate your research with the latest regulatory approval information.

[login](#) or [view full example data](#)

FDA (25)	EMA (0)	NMPA (1)	PMDA (0)		
Production Number	Trade Name	Organization	Market Status	First Appl	Action
EMB4HC203791	Inbravica	Janssen-Cilag International NV	Approved	21 Oct 201	View Detail
	Inbravica	Janssen-Cilag International NV	Approved	21 Oct 201	
	Inbravica	Janssen-Cilag International NV	Approved	21 Oct 201	
	Inbravica	Janssen-Cilag International NV	Approved	21 Oct 201	
	Inbravica	Janssen-Cilag International NV	Approved	21 Oct 201	
	Inbravica	Janssen-Cilag International NV	Approved	21 Oct 201	
	Inbravica	Janssen-Cilag International NV	Approved	21 Oct 201	
	Inbravica	Janssen-Cilag International NV	Approved	21 Oct 201	

Regulation

Understand key drug designations in just a few clicks with Synapse.

[login](#) or [view full example data](#)

Organization	Indication	Regulation	Approved Date
Pharmacylica LLC	Stomach Cancer	Orphan Drug(US)	01 Feb 2018
Xian Janssen Pharmaceuti...	Mantle-Cell Lymphoma	Priority Review(CN)	22 Nov 2017
Xian Janssen Pharmaceuti...	Small Lymphocytic Lymphoma	Priority Review(CN)	22 Nov 2017
Xian Janssen Pharmaceuti...	B-Cell Chronic Lymphocytic Le...	Priority Review(CN)	22 Nov 2017
Pharmacylica LLC	Graft vs Host Disease	Orphan Drug(US)	02 Aug 2017
Pharmacylica LLC	Pancreatic Cancer	Orphan Drug(US)	12 Jun 2017
Pharmacylica LLC	Marginal Zone B-Cell Lymphoma	Accelerated Approval(US)	18 Jan 2017
Janssen-Cilag International ...	Graft vs Host Disease	Orphan Drug(US)	18 Nov 2016
Pharmacylica LLC	Graft vs Host Disease	Orphan Drug(US)	23 Jun 2016
Pharmacylica LLC	Marginal Zone B-Cell Lymphoma	Orphan Drug(US)	02 Feb 2016



AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Hot reports



JMC Annotation Spotlight: Analysis of Breakthrough Therapeutics
Patsnap Synapse



Global Drug R&D Express (February 2025)
PatSnap Synapse



Global Potential Targets and FIC Product Research Report (Q4 2024)
Patsnap Synapse



Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap's AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

[⚡ Start Free Trial](#)

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

[Try Now !](#)

Bio

Bio Sequences Search & Analysis

[Sign up for free !\[\]\(8bba887393ca45b761e5cb49e755e762_img.jpg\)](#)

Chemical

Chemical Structures Search & Analysis

[Sign up for free !\[\]\(0fb13ad0bfa3d86868cdd3883e5665b3_img.jpg\)](#)

Who we are

Solutions

Plan

Contact us: phs@patsnap.com

What we do

Drug

Clinical Progress

Patent

Literature

Report

News

Keep updated



Try Synapse

⚡ Sign Up for Free

PatSnap group products



© 2023 PatSnap. All rights reserved. [Legal](#) | [Privacy Policy](#) | [Modern Slavery Act Transparency Statement](#) | [Manage Cookies](#)